Aptevo Therapeutics Inc. (APVO)Healthcare | Biotechnology | Seattle, United States | NasdaqCM
4.15 USD
+0.21
(5.330%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 4.24 +0.09 (2.070%) ⇧ (July 13, 2026, 7:55 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:14 a.m. EDT
The immediate outlook is severely clouded by a massive 14.5% drop in the last two weeks, leaving the stock trading far below its 50-day average. While analysts have set a lofty $25.50 target, this is disconnected from the brutal reality of the business: the company has suffered four consecutive years of negative annual returns, with the most recent year seeing a nearly 99% collapse in value. This multi-year decline signals a fundamental structural deterioration rather than a temporary setback. Compounding the distress, the company is burning through cash with significant negative free cash flow and no dividend to provide any cushion. The recent news of a reverse split approval and stock tumbling despite positive trial data suggests the market is aggressively repricing the asset for survival, not growth. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.320869 |
| AutoARIMA | 0.329492 |
| AutoETS | 0.329803 |
| MSTL | 0.340960 |
| MSTL_84 | 0.538858 |
| MSTL_115 | 0.572912 |
| MSTL_84_115 | 0.768132 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 12.34 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.068 |
| Excess Kurtosis | -1.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 38.081 |
| Market Cap | 5,171,336 |
| Trailing P/E | 0.00 |
| Forward P/E | -0.19 |
| Beta | 1.67 |
| Website | https://aptevotherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9258004 |
| Address1 | 2,401 4th Avenue |
| Address2 | Suite 1050 |
| All Time High | 68,020,448.0 |
| All Time Low | 3.68 |
| Ask | 5.06 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 160,840 |
| Average Daily Volume3 Month | 54,850 |
| Average Volume | 54,850 |
| Average Volume10Days | 160,840 |
| Beta | 1.671 |
| Bid | 3.06 |
| Bid Size | 2 |
| Book Value | 9.646 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.15 |
| Current Ratio | 3.358 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.29 |
| Day Low | 3.875 |
| Debt To Equity | 38.081 |
| Display Name | Aptevo Therapeutics |
| Dividend Date | 1,585,267,200 |
| Earnings Timestamp End | 1,754,915,400 |
| Earnings Timestamp Start | 1,754,483,400 |
| Ebitda | -26,455,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.186 |
| Enterprise Value | -4,931,664 |
| Eps Current Year | -24.13 |
| Eps Forward | -21.46 |
| Eps Trailing Twelve Months | 1,488.13 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 206 838 0503 |
| Fifty Day Average | 4.755 |
| Fifty Day Average Change | -0.605 |
| Fifty Day Average Change Percent | -0.12723449 |
| Fifty Two Week Change Percent | -92.58004 |
| Fifty Two Week High | 59.4 |
| Fifty Two Week High Change | -55.25 |
| Fifty Two Week High Change Percent | -0.93013465 |
| Fifty Two Week Low | 3.68 |
| Fifty Two Week Low Change | 0.47000003 |
| Fifty Two Week Low Change Percent | 0.12771739 |
| Fifty Two Week Range | 3.68 - 59.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,469,021,400,000 |
| Float Shares | 1,093,632 |
| Forward Eps | -21.46 |
| Forward P E | -0.19338305 |
| Free Cashflow | -17,197,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07967 |
| Held Percent Institutions | 0.044549998 |
| Implied Shares Outstanding | 1,246,105 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,767,052,800 |
| Last Split Factor | 1:18 |
| Long Business Summary | Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. |
| Long Name | Aptevo Therapeutics Inc. |
| Market | us_market |
| Market Cap | 5,171,336 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_331280020 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -26,353,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,909,653 |
| Number Of Analyst Opinions | 2 |
| Open | 3.96 |
| Operating Cashflow | -26,982,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 206 838 0500 |
| Post Market Change | 0.08589983 |
| Post Market Change Percent | 2.0698755 |
| Post Market Price | 4.2359 |
| Post Market Time | 1,783,986,902 |
| Previous Close | 3.94 |
| Price Eps Current Year | -0.17198509 |
| Price Hint | 4 |
| Price To Book | 0.43023017 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.051 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.21 |
| Regular Market Change Percent | 5.32995 |
| Regular Market Day High | 4.29 |
| Regular Market Day Low | 3.875 |
| Regular Market Day Range | 3.875 - 4.29 |
| Regular Market Open | 3.96 |
| Regular Market Previous Close | 3.94 |
| Regular Market Price | 4.15 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 80,549 |
| Return On Assets | -1.18029 |
| Return On Equity | -5.17921 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,246,105 |
| Shares Percent Shares Out | 0.0637 |
| Shares Short | 79,436 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 80,160 |
| Short Name | Aptevo Therapeutics Inc. |
| Short Percent Of Float | 0.0638 |
| Short Ratio | 2.55 |
| Source Interval | 15 |
| State | WA |
| Symbol | APVO |
| Target High Price | 30.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 25.5 |
| Target Median Price | 25.5 |
| Total Cash | 14,525,000 |
| Total Cash Per Share | 11.656 |
| Total Debt | 4,422,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1,488.13 |
| Trailing P E | 0.0027887349 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.18713 |
| Two Hundred Day Average Change | -8.03713 |
| Two Hundred Day Average Change Percent | -0.6594769 |
| Type Disp | Equity |
| Volume | 80,549 |
| Website | https://aptevotherapeutics.com |
| Zip | 98,121 |